BidaskClub upgraded shares of Tocagen (NASDAQ:TOCA) from a sell rating to a hold rating in a research report report published on Friday.
A number of other brokerages have also recently issued reports on TOCA. Zacks Investment Research raised Tocagen from a sell rating to a hold rating in a report on Thursday, January 11th. ValuEngine raised Tocagen from a strong sell rating to a sell rating in a report on Friday, February 2nd. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company’s stock. The company presently has an average rating of Hold and a consensus target price of $23.67.
Tocagen (NASDAQ:TOCA) opened at $13.68 on Friday. Tocagen has a twelve month low of $8.60 and a twelve month high of $17.95. The company has a quick ratio of 6.03, a current ratio of 6.03 and a debt-to-equity ratio of 0.07. The stock has a market capitalization of $270.99 and a P/E ratio of -6.84.
TRADEMARK VIOLATION NOTICE: “Tocagen (TOCA) Raised to “Hold” at BidaskClub” was first reported by Ticker Report and is the property of of Ticker Report. If you are accessing this piece on another site, it was stolen and republished in violation of U.S. & international trademark and copyright law. The legal version of this piece can be viewed at https://www.tickerreport.com/banking-finance/3258548/tocagen-toca-raised-to-hold-at-bidaskclub.html.
Tocagen Inc (Tocagen) is a clinical-stage, cancer-selective gene therapy company. The Company is focused on developing product candidates designed to activate a patient’s immune system against their own cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to selectively deliver therapeutic genes into the deoxyribonucleic acid (DNA) of cancer cells.
Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.